Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Momentum Builds For Tomorrow's More Convenient Hemophilia Drugs

Executive Summary

Updates for a range of new therapies from Roche, Alnylam, BioMarin and Spark Therapeutics at the ISTH meeting in Berlin show progress in development of new hemophilia alternatives, with more late-stage programs kicking off.


Related Content

Alnylam Hopes To Resume Fitusiran Dosing Quickly, Despite Unclear Cause Of Trial Death
ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments
Phase III Updates Bode Well For Filings Of Roche's Emicizumab In Hemophilia
Roche's Emicizumab Progresses Against Hemophilia's Next Big Challenge: Patients With Factor VIII Inhibitors
Patient Death Casts Cloud Over Roche Emicizumab Hemophilia Trial
Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts